Slotnik Capital LLC Sells 142,770 Shares of Inhibrx Biosciences, Inc. $INBX

Slotnik Capital LLC cut its holdings in Inhibrx Biosciences, Inc. (NASDAQ:INBX) by 77.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,401 shares of the company’s stock after selling 142,770 shares during the quarter. Inhibrx Biosciences accounts for 0.4% of Slotnik Capital LLC’s investment portfolio, making the stock its 20th largest holding. Slotnik Capital LLC owned about 0.29% of Inhibrx Biosciences worth $1,394,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of INBX. Strs Ohio acquired a new stake in shares of Inhibrx Biosciences during the 1st quarter worth approximately $27,000. BNP Paribas Financial Markets lifted its position in shares of Inhibrx Biosciences by 71.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock valued at $64,000 after acquiring an additional 789 shares during the period. Bank of America Corp DE lifted its position in shares of Inhibrx Biosciences by 19.2% during the 2nd quarter. Bank of America Corp DE now owns 9,130 shares of the company’s stock valued at $130,000 after acquiring an additional 1,469 shares during the period. Invesco Ltd. bought a new position in Inhibrx Biosciences during the second quarter worth $193,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in Inhibrx Biosciences during the third quarter worth $202,000. 82.46% of the stock is currently owned by institutional investors.

Inhibrx Biosciences Price Performance

Shares of NASDAQ:INBX opened at $68.74 on Friday. Inhibrx Biosciences, Inc. has a twelve month low of $10.81 and a twelve month high of $94.57. The stock’s 50 day moving average is $76.38 and its 200-day moving average is $64.15. The company has a quick ratio of 4.49, a current ratio of 4.49 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $999.48 million, a price-to-earnings ratio of -6.86 and a beta of 1.50.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Inhibrx Biosciences in a report on Thursday, January 22nd. Citigroup reissued a “market perform” rating on shares of Inhibrx Biosciences in a research report on Wednesday, November 19th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Inhibrx Biosciences has a consensus rating of “Reduce”.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.